Literature DB >> 17979170

2'-O-Lysylaminohexyl oligonucleotides: modifications for antisense and siRNA.

Johannes Winkler1, Matthias Gilbert, Aneta Kocourková, Martina Stessl, Christian R Noe.   

Abstract

A novel type of oligonucleotide has been developed, characterized by the attachment of a lysyl moiety to a 2'-O-aminohexyl linker. A protected lysine building block was tethered to 2'-O-aminohexyluridine, and the product was converted into the corresponding phosphoramidite. Up to six modified nucleosides were incorporated in dodecamer DNA and RNA oligonucleotides using standard phosphoramidite chemistry. Each of the building blocks contributes one positive charge to the oligonucleotide instead of the negative charge of a wild-type nucleotide. Thermal denaturation profiles indicated a stabilizing effect of 2'-O-lysylaminohexyl chains that was more pronounced in RNA duplexes. Incubation of the oligonucleotides with 5'-exonuclease revealed an exceptionally high stability against enzymatic degradation. Incorporation of up to three modifications into functional antisense and siRNA oligonucleotides targeted at ICAM-1 showed that the gene-silencing activity was higher with an increasing number of lysylaminohexyl nucleotides. Compared with wild-type antisense or siRNA, compounds with three modifications led to equal or higher ICAM-1 downregulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17979170     DOI: 10.1002/cmdc.200700169

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  4 in total

Review 1.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

2.  EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins.

Authors:  Johannes Winkler; Patricia Martin-Killias; Andreas Plückthun; Uwe Zangemeister-Wittke
Journal:  Mol Cancer Ther       Date:  2009-09-01       Impact factor: 6.261

Review 3.  Oligonucleotide conjugates for therapeutic applications.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2013-07

4.  Oligonucleotides conjugated with short chemically defined polyethylene glycol chains are efficient antisense agents.

Authors:  Nasrin Shokrzadeh; Anna-Maria Winkler; Mehrdad Dirin; Johannes Winkler
Journal:  Bioorg Med Chem Lett       Date:  2014-10-22       Impact factor: 2.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.